Reflections on 10 years of the FDA’s breakthrough therapy designation

被引：0
|
作者：
Asher Mullard
机构：
来源：
Nature Reviews Drug Discovery | 2022年 / 21卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Ellen Sigal, the founder of Friends of Cancer Research, discusses the origins and future of the FDA’s breakthrough therapy designation as well as the changing patient advocacy landscape.
引用
收藏
页码：252 / 253
页数：1
相关论文
共 50 条
  • [31] Breakthrough Therapy Designation for NewDrugs In Reply
    Puthumana, Jeremy
    Wallach, Joshua D.
    Ross, Joseph S.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 320 (19): : 2042 - 2043
  • [32] Erratum: Trends in breakthrough therapy designation
    Rachel R. Chizkov
    Ryan P. Million
    Nature Reviews Drug Discovery, 2016, 15 : 216 - 216
  • [33] FDA Approves Sovaldi for Chronic Hepatitis C (Drug Is Third With Breakthrough Therapy Designation to Receive Such Approval)
    不详
    CLINICAL INFECTIOUS DISEASES, 2014, 58 (05) : I - I
  • [34] Developing Standards for Breakthrough Therapy Designation in Oncology
    Horning, Sandra J.
    Haber, Daniel A.
    Selig, Wendy K. D.
    Ivy, S. Percy
    Roberts, Samantha A.
    Allen, Jeff D.
    Sigal, Ellen V.
    Sawyers, Charles L.
    CLINICAL CANCER RESEARCH, 2013, 19 (16) : 4297 - 4304
  • [35] Stock price effects of breakthrough therapy designation
    Hoffmann, David
    Van Dalsem, Shane
    David, Frank S.
    NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (03) : 165 - 165
  • [36] Characteristics of breakthrough therapy designation requests (BTDRs) submitted to the Office of Hematology and Oncology Products (OHOP), FDA.
    Suzman, Daniel L.
    Kluetz, Paul Gustav
    Mckee, Amy E.
    Ward, Ashley Flynn
    Marcus, Leigh Jessica
    Casak, Sandra J.
    Pazdur, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [37] DOES FDA BREAKTHROUGH DESIGNATION AFFECT HTA RECOMMENDATIONS IN TERMS OF TIMING AND OUTCOME?
    Cai, J.
    Wang, T.
    McAuslane, N.
    Liberti, L.
    VALUE IN HEALTH, 2019, 22 : S809 - S809
  • [38] Breakthrough Therapy Designation: Bringing Innovation Swiftly to Patients
    Arpita Shah
    Therapeutic Innovation & Regulatory Science, 2015, 49 : 256 - 261
  • [39] Breakthrough therapy designation for pancreatic cancer vaccine combo
    不详
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (10) : 2779 - 2780
  • [40] Unveiling the impacts of FDA Breakthrough Therapy Designation: a dual-perspective examination of economic and developmental outcomes for biotechnology companies
    Williamson, Joab
    Spicer, Alexander James
    Louramo, Elina
    Jalkanen, Juho
    DRUG DISCOVERY TODAY, 2024, 29 (04)
12345